A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-393 and Co-administration of CKD-501, D759 and H053 Under Fed Condition in Healthy Adults
Latest Information Update: 10 Aug 2021
At a glance
- Drugs CKD-393 (Primary) ; D 759 (Primary) ; H 053 (Primary) ; Lobeglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 29 Jul 2021 Status changed from not yet recruiting to completed.
- 25 Feb 2021 New trial record